Vita Life Sciences (ASX:VLS) ROCE %: 27.70% (As of Dec. 2025)


ASX:VLS Vita Life Sciences Ltd ASX:VLS
94 GF Score
Price A$2.50
GF Value A$2.47
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Vita Life Sciences ROCE %?

Vita Life Sciences ASX:VLS 94 ROCE % is 27.70% as of Dec. 2025. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Vita Life Sciences's annualized ROCE % for the quarter that ended in Dec. 2025 was 27.70%.

Vita Life Sciences  (ASX:VLS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Vita Life Sciences ROCE % Related Terms

Vita Life Sciences ROCE % Historical Data

* Premium members only.

The historical data trend for Vita Life Sciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vita Life Sciences ROCE % Chart

Vita Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 39.75 31.80 25.24 22.27 26.68

Vita Life Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.67 21.90 26.52 26.06 27.70
ASX:VLS
94GF Score
Vita Life Sciences Ltd ASX:VLS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vita Life Sciences ROCE % Calculation

Vita Life Sciences's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=14.783/( ( (71.892 - 19.274) + (82.362 - 24.165) )/ 2 )
=14.783/( (52.618+58.197)/ 2 )
=14.783/55.4075
=26.68 %

Vita Life Sciences's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=15.606/( ( (74.645 - 20.144) + (82.362 - 24.165) )/ 2 )
=15.606/( ( 54.501 + 58.197 )/ 2 )
=15.606/56.349
=27.70 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 27.70% mean?
Vita Life Sciences (ASX:VLS) has a ROCE % of 27.70% as of Dec. 2025.
Is Vita Life Sciences' ROCE % too high?
Vita Life Sciences' current ROCE % is 27.70%. The Drug Manufacturers industry median ROCE % is 7.00. Vita Life Sciences' value of 27.70% is 296% above this industry median. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' ROCE % compare to ZTS?
Vita Life Sciences' ROCE % of 27.70% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Vita Life Sciences' value of 27.70% is 296% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current ROCE % of 27.70% is 296% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current ROCE % is 27.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current ROCE % is 27.70% and 296% above the Drug Manufacturers industry median of 7.00. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current ROCE % is 27.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?

Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued. The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47. GuruFocus considers Vita Life Sciences to be Fairly Valued.

Key valuation signals for ASX:VLS:

  • ROCE %: 27.70%
  • GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
  • GF Score™: 94/100 with 1 warning sign
  • Industry Position: 296% above the Drug Manufacturers median

No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vita Life Sciences Business Description

Address 1-5 Chalmers Crescent, Suite 802, Level 8, Mascot, Sydney, NSW, AUS, 2020
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score

Get the complete analysis for ASX:VLS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.50
Price
A$2.47
GF Value